China's First TIL Therapy GT101 Granted IND for First-Line Treatment of Head and Neck Squamous Cell Carcinoma

For a 36-year-old cervical cancer patient whose tumors had stopped responding to standard therapies, the experimental treatment offered what conventional medicine could not. After receiving GT101—a therapy derived from her own immune cells—she achieved complete remission within 12 weeks. Fifteen months later, she remains cancer-free.

That patient's story, presented at the American Society of Clinical Oncology annual meeting, represents more than a medical anecdote. It signals a potential shift in how researchers approach solid tumors, long considered the frontier of cellular therapy.

Beijing Grit Biotherapeutics Co., the developer behind GT101, announced Tuesday that China's National Medical Products Administration has granted the company permission to test the therapy in patients with head and neck squamous cell carcinoma. The approval marks the first time China's drug regulator has authorized clinical trials for a tumor-infiltrating lymphocyte therapy, a treatment that harvests immune cells from patients' own tumors and multiplies them in the laboratory before reinfusion.

The new indication—first-line treatment for recurrent or metastatic head and neck cancer—expands GT101's reach beyond cervical cancer, where the therapy is already in late-stage testing. It also represents a strategic bet by Grit Biotherapeutics that cellular therapies can succeed where traditional treatments often fail in solid tumors.

Early Results Show Promise

In the Phase I trial presented at ASCO, GT101 demonstrated an objective response rate of 45.5% among 11 patients with recurrent or metastatic cervical cancer. The disease control rate reached 90.9%, with four patients achieving confirmed partial responses and one patient reaching complete remission.

Median duration of response stood at 6.4 months, while median progression-free survival was 4.83 months. Overall survival data remain under follow-up.

The safety profile proved manageable, according to the company. Most adverse events were Grade 1 or 2. Higher-grade side effects were primarily related to the lymphodepletion pretreatment and interleukin-2 therapy, with most resolving or improving to Grade 2 or below within 14 days. No treatment-related serious adverse events or dose-limiting toxicities were observed.

A Broader Strategy

Grit Biotherapeutics, founded in 2019 by Dr. Liu Yarong, has positioned itself at the intersection of cellular therapy and solid tumor treatment—a space where many biotech companies have struggled to gain traction. The company's pipeline extends beyond GT101.

GT201, described as the world's first TIL product incorporating membrane-bound interleukin-15, has completed dual Investigational New Drug applications in both China and the United States and received approval to enter Phase I clinical trials. The company is also developing a dual gene-edited autologous TIL therapy, mRNA vaccines targeting tumor neoantigens, and what it calls the world's first universal CAR-iNKT cell therapy derived from stem cells.

The head and neck cancer indication represents a calculated expansion. Head and neck squamous cell carcinoma affects more than 800,000 patients globally each year, with limited treatment options for those with recurrent or metastatic disease. The combination of GT101 with PD-1 checkpoint inhibitors reflects an industry trend toward pairing cellular therapies with immune-modulating drugs.

"Solid tumor treatment involves high complexity," Dr. Liu said in a statement. "Patient populations, disease stages, tumor immune microenvironments, and prior treatment histories can all affect the clinical performance of cellular therapy."

The company's approach—building multiple technology platforms in both China and the United States—reflects the ambitions of a new generation of Chinese biotech firms seeking to compete globally rather than license technology from Western counterparts.

Whether GT101 can replicate its cervical cancer results in head and neck cancer remains to be seen. The new clinical trial will provide answers, and perhaps determine whether cellular therapy can finally break through solid tumors' defenses.